Autoimmune CAR-T: Expanding into New Indications

CD19 CAR-T (miv-cel) for stiff-person syndrome and myasthenia gravis BLA expected Q4 2026. In vivo CD19 CAR-T for SLE shows reduced disease activity. BCMA CAR-T shows early promise in refractory ITP. Autoimmune CAR-T field rapidly advancing with multiple clinical trials. Fate Therapeutics initiates potentially registrational trial of off-the-shelf CAR-T FT819 for lupus nephritis; Phase 1 showed no CRS/ICANS/GVHD and outpatient dosing.